Publications

Huang RY, Youssef G, Nelson T, Wen PY, Forsyth P, Hodi FS, Margolin K, Algazi AP, Hamid O, Lao CD, Ernstoff MS, Moschos SJ, Atkins MB, Postow MA, Reardon DA, Grootendorst DJ, Leung D, Askelson M, Ritchings C, Tawbi HA. Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 39752606

Ng DL, Van Loon K, Weidler J, Bates M, Mmbaga EJ, Vuhahula E. FNAB samples with the STRAT4 assay for breast cancer diagnosis - Authors' reply. The Lancet. Oncology. 2025. PMID: 39756449

Wang SJ, Kidder W, Joseph NM, Le BK, Lindsay S, Moon F, Nakakura E, Zhang L, Bergsland EK. Factors associated with grade progression in pancreatic neuroendocrine tumors. Endocrine-related cancer. 2025. PMID: 39813097

Blennemann M, Verma A, Bachl S, Carnevale J, Engelhardt BE. Understanding TCR T cell knockout behavior using interpretable machine learning. Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing. 2025. PMID: 39670384

Trapani D, Jin Q, Miller KD, Rugo HS, Reeder-Hayes KE, Traina T, Abdou Y, Falkson C, Abramson V, Ligibel J, Chen W, Come S, Nohria A, Ryabin N, Tayob N, Tolaney SM, Burstein HJ, Mayer EL. Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE Clinical Trials. Clinical breast cancer. 2024. PMID: 39890560

Banerjee S, Le P, Yang H, Zhang L and He T. TCR-NP: a novel approach to prioritize T-cell receptor repertoire network properties Statistics Innovation. 2024. PMID:

Gaballa MR, Castaneda Puglianini O, Cohen AD, Vogl DT, Chung A, Ferreri CJ, Voorhees PM, Hansen DK, Patel KK. BCMA-directed CAR T-cell Therapy in patients with multiple myeloma and CNS involvement. Blood advances. 2024. PMID: 39729503

Xu MJ, Haddadi S, Mushi BP, Zhang L, Sama G, Nyagabona SK, Ng D, Muya S, Malango AE, Richard E, Ha P, Yom SS, Massawe W, Mmbaga EJ, Van Loon K, Nkya A. Treatment initiation and completion among head and neck squamous cell carcinoma patients in Tanzania. BMC research notes. 2024. PMID: 39716326

Thiruvengadam SK, Merryman R, Wang Y, Gaulin C, Bezerra E, Voorhees T, Seshadri MR, Falade A, Habib A, Ayers AA, Bailey M, Brown A, Bailey N, Patel K, Andreadis CB, Kittai AS, Jacobson C, Palmer J, Forman SJ, Nastoupil L, Budde LE. Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma. American journal of hematology. 2024. PMID: 39715004

Jindal T, Jiang C, Alhalabi O, Nizam A, Nguyen C, Talukder R, Bakaloudi D, Davidsohn M, Freeman D, Glover M, Khaki AR, Evans S, Lemke E, Bose R, Sim W, Pywell C, Basu A, Kilari D, Barata PC, Bilen MA, Zakharia Y, Milowsky MI, Shah SA, Bellmunt J, Grivas P, Emamekhoo H, Davis NB, Gupta S, Hoimes C, Campbell MT, Alva A, Koshkin VS. Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data. European urology oncology. 2024. PMID: 39709257

Koshkin VS, Danchaivijitr P, Bae WK, Semenov A, Ozyilkan O, Su YL, Arranz Arija JA, Tsujihata M, Bögemann M, Hendriks MP, Delgado SN, Rosenbaum E, Lopez KA, Bavle A, Liu CC, Imai K, Furka A. Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy. European urology. 2024. PMID: 39709248

Goyal L, DiToro D, Facchinetti F, Martin EE, Peng P, Baiev I, Iyer R, Maurer J, Reyes S, Zhang K, Majeed U, Berchuck JE, Chen CT, Walmsley C, Pinto C, Vasseur D, Gordan JD, Mody K, Borad M, Karasic T, Damjanov N, Danysh BP, Wehrenberg-Klee E, Kambadakone AR, Saha SK, Hoffman ID, Nelson KJ, Iyer S, Qiang X, Sun C, Wang H, Li L, Javle M, Lin B, Harris W, Zhu AX, Cleary JM, Flaherty KT, Harris T, Shroff RT, Leshchiner I, Parida L, Kelley RK, Fan J, Stone JR, Uboha NV, Hirai H, Sootome H, Wu F, Bensen DC, Hollebecque A, Friboulet L, Lennerz JK, Getz G, Juric D. A Model for Decoding Resistance in Precision Oncology: Acquired Resistance to FGFR inhibitors in Cholangiocarcinoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2024. PMID: 39706336

Lingappa AF, Akintunde O, Samueli E, Ewald C, Michon M, Ziari N, Lu M, Yu SF, Froehlich M, Le PU, Fernandez Y, Mallesh S, Lin J, Kitaygorodskyy A, Solas D, Reed JC, Lingappa JR, Müller-Schiffmann A, Korth C, Prasad D, Nalca A, Aston E, Fabbri B, Anand SK, Campi TW, Petrouski E, Dey D, Andrews DW, Rubenstein JL, Lingappa VR. Small molecule protein assembly modulators with pan-cancer therapeutic efficacy. Open biology. 2024. PMID: 39689856

Oliai C, Park S, Damon LE, Jonas BA, Jeyakumar D, Wieduwilt MJ, Logan AC, Callas B, Hannigan CA, Gaut DL, Schiller GJ. CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial. Leukemia & lymphoma. 2024. PMID: 39689718

Truong AA, Lee RH, Wu X, Algazi AP, Kang H, El-Sayed IH, George JR, Heaton CM, Ryan WR, Jeon Y, Kim MO, Ha PK, Wai KC. Neutrophil-to-Lymphocyte Ratio and Pembrolizumab Outcomes in Oral Cavity Squamous Cell Carcinoma. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2024. PMID: 39675043

Shang J, Del Valle DM, Britton GJ, Mead KR, Rajpal U, Chen-Liaw A, Mogno I, Li Z, Menon R, Gonzalez-Kozlova E, Elkrief A, Peled JU, Gonsalves TR, Shah NJ, Postow M, Colombel JF, Gnjatic S, Faleck DM, Faith JJ. Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis. The Journal of experimental medicine. 2024. PMID: 39666007

Arce MM, Umhoefer JM, Arang N, Kasinathan S, Freimer JW, Steinhart Z, Shen H, Pham MTN, Ota M, Wadhera A, Dajani R, Dorovskyi D, Chen YY, Liu Q, Zhou Y, Swaney DL, Obernier K, Shy BR, Carnevale J, Satpathy AT, Krogan NJ, Pritchard JK, Marson A. Central control of dynamic gene circuits governs T cell rest and activation. Nature. 2024. PMID: 39663454

Lee HJ, Boscardin J, Walter LC, Smith AK, Cohen HJ, Giri S, Williams GR, Presley CJ, Singhal S, Huang LW, Velazquez AI, Gubens MA, Blakely CM, Mulvey CK, Cheng ML, Sakoda LC, Kushi LH, Quesenberry C, Liu R, Fleszar-Pavlovic S, Eskandar C, Cutler E, Mercurio AM, Wong ML. Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancer. The oncologist. 2024. PMID: 39657913

Turnham RE, Pitea A, Jang GM, Xu Z, Lim HC, Choi AL, Von Dollen J, Levin RS, Webber JT, McCarthy E, Hu J, Li X, Che L, Singh A, Yoon A, Chan G, Kelley RK, Swaney DL, Zhang W, Bandyopadhyay S, Theis FJ, Eckhardt M, Chen X, Shokat KM, Ideker T, Krogan NJ, Gordan JD. HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma. Cancer research. 2024. PMID: 39652575

Landgren CO, Chari A, Cohen YC, Spencer A, Voorhees PM, Sandhu I, Jenner MW, Smith D, Cavo M, van de Donk NWCJ, Beksac M, Moreau P, Goldschmidt H, Vieyra D, Sha L, Li L, Rousseau E, Dennis RM, Carson R, Hofmeister CC. Efficacy and Safety of Daratumumab in Intermediate/High-risk Smoldering Multiple Myeloma: Final Analysis of CENTAURUS. Blood. 2024. PMID: 39652826